Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PF-07284892 in Participants With Advanced Solid Tumors
NCT04800822 · Pfizer · PHASE1 · terminated · last registry update 2026-06-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, Abemaciclib + PI3K Inhibitor paxalisib (NCT03994796)
- 2026-10-09Results posted on the registry: Hoffmann-La Roche, Alectinib + Crizotinib (NCT03194893)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Ensartinib (NCT03213652)
- 2026-09-11Phase 3 first posted: Guangzhou JOYO Pharma Co., Ltd, JYP0322 Tablets + Crizotinib Capsules (NCT07816380)
- 2026-09-04Phase 3 first posted: IDEAYA Biosciences, Darovasertib + Crizotinib (Xalkori) (NCT07804186)
- 2026-07-21Also stopped (terminated): ETOP IBCSG Partners Foundation, Alectinib (NCT03445000)
- 2026-06-05Also stopped (suspended): Megan Kruse, MD, Taletrectinib (NCT06214793)
- 2026-04-30Results posted on the registry: Xcovery Holdings, Inc., Phase I: X-396 (ensartinib) + Phase II: X-396 (ensartinib) (NCT01625234)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-03-20Results posted on the registry: National Cancer Institute (NCI), Crizotinib (NCT06360575)
- 2026-03-19Results posted on the registry: National Cancer Institute (NCI), Crizotinib (NCT06357975)
- 2026-03-13Results posted on the registry: University of Alabama at Birmingham, Crizotinib (NCT04283669)
- 2026-03-10Also stopped (terminated): Yael P Mosse, Next Generation Sequencing + Ribociclib (NCT02780128)
- 2025-10-30Results posted on the registry: Royal Marsden NHS Foundation Trust, Crizotinib Oral Capsule [Xalkori] + Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic] (NCT03620643)
- 2025-09-15Results posted on the registry: New Approaches to Neuroblastoma Therapy Consortium, Lorlatinib + Cyclophosphamide (NCT03107988)
- 2025-07-16Also stopped (terminated): National Cheng-Kung University Hospital, Crizotinib 250 MG (NCT04030429)
- 2025-06-11Results posted on the registry: Pfizer, Lorlatinib (NCT04362072)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision